ANIK — Anika Therapeutics, Inc.

Summary of Anika's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $27.8 million, down 6% year-over-year.
• Commercial Channel Revenue: $12 million, up 22% year-over-year, driven by strong growth in the regenerative solutions portfolio.
• OEM Channel Revenue: $15.8 million, down 20% year-over-year, primarily due to pricing pressures.
• Gross Margin: 56%, a decrease of 10 percentage points year-over-year but an improvement of 5 percentage points sequentially.
• Operating Expenses: $18.8 million, down 3% year-over-year, with SG&A expenses down 12%.
• Adjusted EBITDA: Positive $900,000, a decline of $3.7 million year-over-year but an improvement over the previous quarter.
• Operating Cash Flow: $6.9 million, up from $5 million in the same period last year.
• Cash Position: $58 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Regulatory Progress: Submitted the third and final PMA module for Hyalofast and advanced toward the NDA filing for Cingal.
• Integrity Growth: Continued momentum with a 25% year-over-year growth in regenerative solutions, with plans to double procedures in 2025.
• International Expansion: International OA Pain Management revenue grew 21% year-over-year, with over 1 million Cingal injections sold since its launch.
• Cost Management: Successful reduction in operating expenses and improved profitability through strategic cost-saving initiatives.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Maintaining expectations for Commercial Channel revenue between $47 million and $49.5 million (12% to 18% growth) and OEM Channel revenue between $62 million and $65 million (16% to 20% decline).
• Adjusted EBITDA Guidance: Maintaining a range of positive 3% to negative 3%.
• Share Repurchase Program: Initiating a second $15 million share repurchase under a previously announced program.

4. Bad News, Challenges, or Points of Concern

• Declining OEM Revenue: Significant decline in OEM channel revenue due to pricing pressures and a shift towards single-injection treatments.
• Gross Margin Volatility: While margins improved sequentially, year-over-year declines raise concerns about pricing stability, particularly with J&J.
• Regulatory Risks: The Hyalofast Phase III study did not meet its primary endpoints, which could impact FDA approval and market perception.
• Production Issues: Ongoing challenges from earlier production disruptions affecting order fulfillment, although recovery is underway.

5. Notable Q&A Insights

• Integrity Utilization: The focus on increasing surgeon adoption and training to expand the user base and procedure volume.
• Cingal Timeline: The timeline for completing the bioequivalence study and toxicity studies is still being finalized, with updates expected in the next earnings call.
• Capital Deployment: Prioritization of internal investments for product growth and manufacturing capacity over share repurchases, with M&A not currently on the agenda.
• Gross Margin Expectations: Future gross margins are expected to stabilize between 55% and 60%, contingent on pricing dynamics with J&J.

Overall, Anika's Q3 2025 results reflect a mixed performance with strong growth in certain areas but significant challenges in others, particularly in the OEM channel and regulatory landscape. The company remains focused on strategic growth initiatives and maintaining financial discipline.